Recent trials

Trials recently included in TrialResults-center.org RSS


Hyams, (16807)
NCT00454805
cediranib + fulvestrant vs fulvestrant
in advanced breast cancer (metastatic)

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

De Jong, (16806)enzastaurin + fulvestrant vs Fulvestrant
in advanced breast cancer (metastatic)

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

LEA, (16805)bevacizumab + endocrine therapy vs endocrine therapy
in advanced breast cancer (metastatic)

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

angiogenesis inhibitors for advanced breast cancer (metastatic) in first line therapy

Dickler (CALGB 40503°, 2015 (16804)Letrozole plus bevacizumab vs letrozole
in advanced breast cancer (metastatic)

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

Aphinity, (16758)
NCT01358877
pertuzumab vs placebo
in early breast cancer

HER2 inhibitors for early breast cancer in HER2 positive patients

ASCEND-4, 2017 (16742)
NCT01828099
ceritinib vs chemotherapy
in lung cancer

ALK inhibitors for lung cancer in ALK positive patients

EGFR inhibitors for lung cancer in all type of patients

IMvigor211, (16737)
NCT02302807
atezolizumab vs chemotherapy
in advanced urothelial carcinoma

immune checkpoint inhibition for advanced urothelial carcinoma in all type of patients

KEYNOTE-045, (16736)
NCT02256436
pembrolizumab vs investigator’s choice of chemotherapy
in advanced urothelial carcinoma

immune checkpoint inhibition for advanced urothelial carcinoma in all type of patients

EUCLID, 2016 (16722)
NCT01732822
ticagrelor vs clopidogrel
in peripheral vascular diseases

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

EUCLID, 2016 (16722)
NCT01732822
ticagrelor vs clopidogrel
in cardiovascular prevention

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

NESTOR, 2004 (16714) vs
in diabetic kidney disease

All mechanism for diabetic kidney disease in all type of patients

TOPCAT, 2014 (16700)
NCT00094302
spironolactone vs placebo
in heart failure

diuretics for heart failure in patients with preserved-LVEF heart failure

mineralocorticoid receptor antagonists for heart failure in all type of patients

mineralocorticoid receptor antagonists for heart failure in HF pEF

All mechanism for heart failure with preserved LVEF in all type of patients

TOPCAT, 2014 (16700)
NCT00094302
spironolactone vs placebo
in heart failure with preserved LVEF

diuretics for heart failure in patients with preserved-LVEF heart failure

mineralocorticoid receptor antagonists for heart failure in all type of patients

mineralocorticoid receptor antagonists for heart failure in HF pEF

All mechanism for heart failure with preserved LVEF in all type of patients

Edlemann, 2013 (16699) vs
in heart failure with preserved LVEF

All mechanism for heart failure with preserved LVEF in all type of patients

PARAMOUNT, 2012 (16698)
NCT00887588
LCZ696 vs valsartan
in heart failure with preserved LVEF

All mechanism for heart failure with preserved LVEF in all type of patients

ADOPT, 2011 (16691)
NCT00457002
apixaban vs enoxaparin
in DVT prophylaxis

antithrombotics for DVT prophylaxis in medical patients

direct oral anticoagulant (DAO) for DVT prophylaxis in medical patients

AURA 3, (16655)
NCT02151981
Osimertinib vs
in lung cancer

EGFR inhibitors for lung cancer in all type of patients

CADUCEUS, 2012 (16620)
NCT00893360
Cardiopoietic stem cell vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Perin, 2012 (16619)Bone marrow progenitor cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Vrtovec, 2013 (16618)
NCT01350310
Bone marrow progenitor cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Vrtovec, 2011 (16617)
NCT00629018
Bone marrow progenitor cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Manginas, 2007 (16616)Bone marrow progenitor cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Patel, 2005 (16615)Bone marrow progenitor cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Ang, 2008 (16614)Bone marrow mononuclear cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Yao, 2008 (16613)Bone marrow mononuclear cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Hendrikx, 2006 (16612)Bone marrow mononuclear cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

TOPCARE-CHD, 2006 (16611)
NCT00289822
Bone marrow mononuclear cells vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

C CURE, 2013 (16610)
NCT00810238
Cardiopoietic stem cell vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

Catheter-DCM, 2014 (16603)
NCT01020968
ixmyelocel-T vs control
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients

MARVEL, 2011 (16602)
NCT00526253
myoblasts vs placebo
in heart failure

cell-based therapies for heart failure in all types of patients

regenerative therapy for heart failure in all type of patients